Point72 Europe (London) LLP Repligen Corp Transaction History
Point72 Europe (London) LLP
- $1.97 Billion
- Q3 2025
A detailed history of Point72 Europe (London) LLP transactions in Repligen Corp stock. As of the latest transaction made, Point72 Europe (London) LLP holds 952 shares of RGEN stock, worth $145,056. This represents 0.01% of its overall portfolio holdings.
Number of Shares
952Holding current value
$145,056% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding RGEN
# of Institutions
524Shares Held
58.9MCall Options Held
323KPut Options Held
667K-
Black Rock Inc. New York, NY7.57MShares$1.15 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.04MShares$769 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.51MShares$534 Million0.05% of portfolio
-
United Capital Financial Advisers, LLC Newport Beach, CA2.76MShares$420 Million2.74% of portfolio
-
State Street Corp Boston, MA1.8MShares$275 Million0.01% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $8.46B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....